Related Experiment Video
Updated: May 7, 2026

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
Published on: October 4, 2016
What the Non-Psychiatrist Should Know About Transcranial Magnetic Stimulation for Major Depression
Pilar Cristancho1, Jeanne Therese Hagemeister2, Darin Quach3
1Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
None:
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment for major depressive disorder. Randomized controlled trials show response rates twice times higher for TMS (23.9%) than placebo (12.3%) in adults with depression. Real world studies showed increased response rates up to 58% in clinically heterogenous adult patient populations. TMS is safe and well tolerated with a benign side effect profile and high adherence. Standard TMS protocols include left dorso-lateral prefrontal cortex stimulation using a fixed stimulation protocol or burst-patterned protocols such as intermittent theta burst delivered over six weeks. Novel accelerated protocols using high daily dosing and functional MRI targeting provide increased precision and improved treatment outcomes. TMS shows effectiveness in patients with comorbid anxiety, older adults and adolescents for which received FDA approval in 2024. Future studies incorporating neuroimaging techniques may help to refine protocols leading to improved outcomes across different patient populations.
Related Concept Videos
G-protein Coupled Receptors
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents

